ANTI-CD20 THERAPY

Clinical trials for ANTI-CD20 THERAPY explained in plain language.

Never miss a new study

Get alerted when new ANTI-CD20 THERAPY trials appear

Sign up with your email to follow new studies for ANTI-CD20 THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

MS breakthrough? trial tests if older patients can ditch heavy drugs

Disease control Not yet recruiting

This study looks at whether people with relapsing-remitting multiple sclerosis (MS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to a milder therapy without their disease coming back. Half the participants will stay on thei…

Matched conditions: ANTI-CD20 THERAPY

Phase: PHASE3 • Sponsor: University Hospital, Montpellier • Aim: Disease control

Last updated May 17, 2026 16:05 UTC

ANTI-CD20 THERAPY

Get alerted when new ANTI-CD20 THERAPY trials appear

MS breakthrough? trial tests if older patients can ditch heavy drugs